Investigational Drug Information for Nirmatrelvir
✉ Email this page to a colleague
What is the development status for investigational drug Nirmatrelvir?
Nirmatrelvir is an investigational drug.
There have been 23 clinical trials for Nirmatrelvir.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2023.
The most common disease conditions in clinical trials are COVID-19, Inflammation, and Disease. The leading clinical trial sponsors are Pfizer, Vigonvita Life Sciences, and The Affiliated Hospital Of Southwest Medical University.
There is one US patent protecting this investigational drug and forty-four international patents.
Summary for Nirmatrelvir
US Patents | 1 |
International Patents | 44 |
US Patent Applications | 4 |
WIPO Patent Applications | 3 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 3 (2023-01-21) |
Vendors | 27 |
Recent Clinical Trials for Nirmatrelvir
Title | Sponsor | Phase |
---|---|---|
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms | Kanecia Obie Zimmerman | Phase 2 |
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin | Pfizer | Phase 1 |
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities | National Taiwan University Hospital | Phase 2/Phase 3 |
Clinical Trial Summary for Nirmatrelvir
Top disease conditions for Nirmatrelvir
Top clinical trial sponsors for Nirmatrelvir
US Patents for Nirmatrelvir
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
nirmatrelvir | ⤷ Sign Up | ⤷ Sign Up | ||
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Nirmatrelvir
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
nirmatrelvir | Argentina | AR123111 | 2040-09-03 | ⤷ Sign Up |
nirmatrelvir | Australia | AU2021266232 | 2040-09-03 | ⤷ Sign Up |
nirmatrelvir | Australia | AU2022202158 | 2040-09-03 | ⤷ Sign Up |
nirmatrelvir | Australia | AU2022221493 | 2040-09-03 | ⤷ Sign Up |
nirmatrelvir | Brazil | BR112021022419 | 2040-09-03 | ⤷ Sign Up |
nirmatrelvir | Canada | CA3137824 | 2040-09-03 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |